Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial by Perez, Edith A. et al.
ARTICLE
Intrinsic Subtype and Therapeutic Response Among
HER2-Positive Breast Tumors from the NCCTG
(Alliance) N9831 Trial
Edith A. Perez, Karla V. Ballman, Afshin Mashadi-Hossein,
Kathleen S. Tenner, Jennifer M. Kachergus, Nadine Norton,
Brian M. Necela, Jennifer M. Carr, Sean Ferree, Charles M. Perou,
Frederick Baehner, Maggie Chon U. Cheang, E. Aubrey Thompson
Affiliations of authors: Division of Hematology/Oncology, Department of Medicine (EAP), and Department of Cancer Biology (EAP, JMK, NN, BMN, JMC, EAT), Mayo Clinic
Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL; Division of Biostatistics and Bioinformatics, Department of Health Science Research, Mayo Clinic
Comprehensive Cancer Center, Mayo Clinic, Rochester, MN (KVB, KST); Nanostring, Inc., Seattle, WA (AMH, SF); Departments of Genetics and Pathology & Laboratory
Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (CMP, MCUC); Genonic Health, Inc., Redwood, CA (FB); Clinical Trials
and Statistics Unit, The Institute of Cancer Research, London, UK (MCUC).
Correspondence to: E. Aubrey Thompson, PhD, Department of Cancer Biology, Griffin Cancer Research Bld., Rm 214, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL
32224 (e-mail: thompson.aubrey@mayo.edu).
Abstract
Background: Genomic data from human epidermal growth factor receptor 2–positive (HER2þ) tumors were analyzed to assess
the association between intrinsic subtype and clinical outcome in a large, well-annotated patient cohort.
Methods: Samples from the NCCTG (Alliance) N9831 trial were analyzed using the Prosigna algorithm on the NanoString
platform to define intrinsic subtype, risk of recurrence scores, and risk categories for 1392 HER2þ tumors. Subtypes were
evaluated for recurrence-free survival (RFS) using Kaplan-Meier and Cox model analysis following adjuvant chemotherapy
(n¼484) or chemotherapy plus trastuzumab (n¼908). All statistical tests were two-sided.
Results: Patients with HER2þ tumors from N9831 were primarily scored as HER2-enriched (72.1%). These individuals received
statistically significant benefit from trastuzumab (hazard ratio [HR] ¼ 0.68, 95% confidence interval [CI] ¼ 0.52 to 0.89, P ¼ .005),
as did the patients (291 of 1392) with luminal-type tumors (HR¼0.52, 95% CI¼0.32 to 0.85, P ¼ .01). Patients with basal-like tu-
mors (97 of 1392) did not have statistically significantly better RFS when treated with trastuzumab and chemotherapy compared
with chemotherapy alone (HR¼1.06, 95% CI¼0.53 to 2.13, P ¼ .87).
Conclusions: The majority of clinically defined HER2-positive tumors were classified as HER2-enriched or luminal using the
Prosigna algorithm. Intrinsic subtype alone cannot replace conventional histopathological evaluation of HER2 status because
many tumors that are classified as luminal A or luminal B will benefit from adjuvant trastuzumab if that subtype is accompa-
nied by HER2 overexpression. However, among tumors that overexpress HER2, we speculate that assessment of intrinsic
subtype may influence treatment, particularly with respect to evaluating alternative therapeutic approaches for that subset
of HER2-positive tumors of the basal-like subtype.
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Article
With the advent of high-dimensional technologies for quantify-
ing expression of large numbers of genes, it has become clear
that breast tumors exhibit a considerable range of molecular/ge-
nomic heterogeneity, both between and among the clinically
defined cohorts of hormone receptor–positive, human epider-
mal growth factor receptor 2 (HER2)–positive, and triple-negative
tumors. The most thoroughly characterized classifier of molecu-
lar heterogeneity is the PAM50 signature (1,2), which uses the ex-
pression of 50 genes to stratify breast tumors into four major
classes: basal-like, HER2-enriched, luminal A, and luminal B.
There is a strong presupposition that these biological processes
will prove to be informative of clinical/pathological features of
breast tumors (2–6).
Our studies have focused upon defining molecular heteroge-
neity among HER2-positive (HER2þ) breast tumors. We used the
NanoString Prosigna algorithm and PAM50 genes to define in-
trinsic subtypes and assess their distribution and association
with outcome within tumors from the North Central Cancer
Treatment Group (NCCTG [Alliance]) N9831 trial of patients with
early-stage HER2þ tumors (7,8) randomly assigned to receive
adjuvant chemotherapy or chemotherapy plus trastuzumab.
Our primary analytical focus was to test the hypothesis that
benefit from adjuvant chemotherapy combined with trastuzu-
mab, compared with benefit from adjuvant chemotherapy
alone, varies as a function of intrinsic subtype.
Methods
Patients
The NCCTG (Alliance) N9831 trial enrolled 3505 patients
who were randomly assigned to three study arms: arm A—
chemotherapy (doxorubicin and cyclophosphamide followed by
weekly paclitaxel); arm B—chemotherapy followed by 52 weeks
of weekly trastuzumab; and arm C—chemotherapy with
12 weeks of trastuzumab concurrent with paclitaxel, followed
by 40 more weeks of weekly trastuzumab alone, as previously
described in detail (7). Patients in both trastuzumab-treated
arms (B and C) received 52 weeks of trastuzumab and showed
statistically significant improvement in relapse-free survival
(7,8), compared with patients who received chemotherapy alone
(arm A). We therefore combined patients from arms B and C
into a single trastuzumab-treated group (arm B/C) for subse-
quent analysis. All patients included in this analysis were as-
sessed for central HER2 immunohistochemistry (IHC) and/or
fluorescence in situ hybridization (FISH) as part of the N9831
parent study, as previously described (7). Informed written con-
sent to these studies was obtained from all patients. Studies
were carried out under Mayo Clinic Institutional Review Board
protocols 954-00 and 13-000290.
Statistical Analysis
The main objective of the analysis was to determine whether the
effect of trastuzumab qualitatively differed for any of the intrinsic
subtypes. If differing treatment effects were observed among the
subtypes, a test for interaction was to be performed to determine
whether this observation was statistically significant. The pri-
mary endpoint for outcome analysis was recurrence-free survival
(RFS), defined as the time from random assignment to breast can-
cer recurrence (local, regional, or distant recurrence of breast can-
cer or breast cancer–related death). The time to event for patients
who died without recurrence was considered censored at the
time of death. Cox proportional hazard models were used to gen-
erate point estimates of hazard ratios (HRs) and corresponding
95% confidence intervals (CIs) to assess the benefit of trastuzu-
mab for RFS comparisons. The assumption of proportional haz-
ards was verified with a Cox proportional hazard model
containing the treatment indicator and the interaction of the indi-
cator with the log of time. The test of proportionality involves a
likelihood ratio test of the model containing the interaction term
against the model that contains the treatment variable only. A
nonsignificant P value of this test suggests there is not sufficient
evidence to reject the assumption of proportional hazards. The P
value of this test was .88, suggesting that there is not sufficient
evidence to reject the assumption of proportional hazards. Wald
Chi-squared P values were calculated for the Cox hazard ratios.
Comparisons were made both within and between treatment
arms. The interaction term of basal-like vs non-basal-like by
treatment arm was determined using a Cox model that also in-
cluded the main effects; this interaction was tested because the
effect of trastuzumab appeared qualitatively different in this sub-
type. Kaplan-Meier plots were used to depict the proportion of pa-
tients free from breast cancer recurrence as a function of time.
Chi-squared tests for nominal categories or Cochran-Mantel-
Haenszel tests for ordered categories were performed to ascertain
differences in eligible N9831 patients included in the analysis
with those that were excluded. All statistical tests were two-
sided, and a P value of less than .05 was considered statistically
significant.
Assignment of Intrinsic Subtype
We constructed a NanoString custom CodeSet that includes the
PAM50 genes plus appropriate housekeeping genes (B2M,
GAPDH, POLR2A, UBC, YWHAZ) for normalization purposes. The
Prosigna subtyping algorithm is trained for use with Prosigna
CodeSet. To use this algorithm for subtyping N9831 data, adjust-
ment factors that account for differences between the custom
CodeSet used in the N9831 study and the Prosigna CodeSet were
estimated and applied to the data. To this end, 30 samples,
which were processed with the custom CodeSet, were repro-
cessed using the Prosigna CodeSet. For each probe, this pro-
vided 30 pairs of counts (corresponding to the two CodeSets),
which were then used to estimate the adjustment factor be-
tween the two CodeSets. Specifically, for each of the PAM50
probes, first the ratio of the normalized counts from the custom
CodeSet relative to their corresponding normalized counts from
the Prosigna CodeSet were calculated, resulting in 30 ratios for
each of the probes. Then, for each probe, the median of the 30
ratios was taken as the adjustment factor. Subsequently, the re-
sultant 50 adjustment factors (one for each PAM50 gene) were
applied to the PAM50 counts in the original data set and subtyp-
ing was performed on the adjusted counts per standard
Prosigna algorithm. Quantitative real-time polymerase chain re-
action data on mRNA abundance, proliferative scores, and mi-
totic indices were abstracted from a published study on the
OncotypeDX analysis of N9831 samples (9).
Results
Assignment of Risk Scores and Intrinsic Subtype
Using Prosigna
Samples from 1426 eligible patients had sufficient RNA for test-
ing and were analyzed on the NanoString platform to measure
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the abundance of mRNAs that define the intrinsic subtype pat-
terns. Thirty-four samples were excluded for quality control is-
sues, mostly low total gene counts; 1392 remaining samples
(arm A: 484, arm B: 494, arm C: 414) were analyzed for intrinsic
subtype in a blinded fashion. Patient demographics for samples
that were included, as well as those from whom RNA was not
available, are given in Supplementary Table 1 (available online).
Distributions of intrinsic subtypes, risk of recurrence scores
(ROR), and risk categories (high, intermediate, low) as a function
of treatment arm are given in Table 1, and clinical/pathological
features of the tumors by treatment are in Supplementary Table 2
(available online). There were small but statistically significant
differences in nodal status between the two arms (P ¼ .04).
However, the observed increase in node 0 and node 1–3 patients
in arm B/C did not translate into differences in risk category
(Table 1).
The patients enrolled in N9831 were centrally confirmed as
HER2þ. The majority of the tumors (1004 of 1392, 72.1%) were
classified by Prosigna as HER2-enriched. The remaining tumors
were more or less equally distributed among the basal-like (97
of 1392, 7.0%), luminal A (132 of 1392, 9.5%), or luminal B (159 of
1392, 11.4%) subtypes.
Association Between Risk of Recurrence Score,
Risk Category, and RFS
The Prosigna algorithm reports a risk of recurrence score that
combines intrinsic subtype, tumor size, and proliferation score
into a single metric. The majority of the N9831 samples (1045/
1392) had ROR scores above 70, where low risk is considered 1–
40, intermediate risk 40–60, and high risk above 60. We did not
observe a statistically significant association between RFS and
ROR, expressed as a discontinuous, quantile score, among pa-
tients who received chemotherapy alone (arm A, P¼ .40) (Figure 1A)
or patients who received chemotherapy plus trastuzumab (arms
B/C, P ¼ .37) (Figure 1B).
Tumor size is incorporated into ROR to stratify tumors into
high-, intermediate-, and low-risk categories. Almost all of the
N9831 samples were classified as high risk (1335/1392) (Table 1).
The Kaplan-Meier analysis suggested a quantitative tendency
toward improved RFS in the few low-/intermediate-risk patients
who received chemotherapy alone; however, this tendency did
not achieve statistical significance (arm A, P ¼ .13) (Figure 1C).
Low-/intermediate-risk patients who received trastuzumab ap-
peared to receive statistically significant benefit (arm B/C,
P ¼ .01) (Figure 1D). Among the tumors with low/intermediate
risk, those classified as estrogen receptor– and/or progester-
one receptor–positive seldom recurred. Among 30 such pa-
tients, only one recurrence was reported, compared with the
overall recurrence rate of about one in four (317/1392) for all
patients in this study (Chi-squared P ¼ .01).
A subset of the N9831 patients (445 from arm A and 397 from
arm C) has previously been analyzed using the 21-gene
OncotypeDX panel (9). As with the Prosigna analysis, almost all
of the patients were classified as high risk (763/842). A number
of molecular features associated with subtype were derived
from the 21-gene signature, including ERBB2 mRNA, prolifera-
tive score, and Ki67 mRNA. Percent cells staining 3þ for HER2
was extracted from the clinical record, and mitotic index was
assessed by histological examination, as shown in Table 2. The
proliferative markers associated with each subtype were ranked
basal-like > HER2-enriched  luminal B > luminal A. HER2 ex-
pression generally followed the pattern HER2-enriched > lumi-
nal A > luminal B > basal-like. Among the four subtypes, the
basal-like tumors exhibited the lowest HER2 expression and the
highest proliferation, features that might be expected to influ-
ence outcome following HER2-targeted therapy.
Association Between Intrinsic Subtype and RFS
A statistically significant association between RFS and intrinsic
subtype was observed when all patients (irrespective of therapy)
were evaluated (Figure 2A). Patients with basal-like tumors ex-
hibited statistically significantly worse RFS compared with pa-
tients with HER2-enriched, luminal A, or luminal B subtypes.
When intrinsic subtype was evaluated within each treatment
arm, there was no statistically significant association between
subtype and RFS in the patients who received chemotherapy
alone (HRbasal ¼ reference, log-rank P ¼ .79; HRHER2 ¼ 0.75,
95% CI¼ 0.42 to 1.33, P ¼ .32; HRlumA ¼ 0.76, 95% CI¼ 0.35 to
1.64, P¼ .32; HRlumB¼ 0.83, 95% CI¼ 0.41 to 1.69, P¼ .61) (Figure 2B).
However, a statistically significant association was observed be-
tween outcome and intrinsic subtype among patients who re-
ceived trastuzumab (HRbasal ¼ reference, log-rank P ¼ .007;
HRHER2 ¼ 0.49, 95% CI¼ 0.30 to 0.78, P ¼ .003; HRlumA ¼ 0.47,
95% CI¼ 0.25 to 0.90, P ¼ .02; HRlumB ¼ 0.35, 95% CI¼ 0.18 to
0.68, P ¼ .002) (Figure 2C).
RFS as a Function of Treatment and Subtype
The data in Figure 2 suggest that there is a relationship between
intrinsic subtype and outcome and that this relationship resides
primarily in those patients who received adjuvant trastuzumab.
We therefore evaluated the relationship between RFS and treat-
ment within each subtype. Trastuzumab appeared to have little
or no statistically significant association with RFS in HER2þ pa-
tients of the basal-like subtype (HR¼ 1.06, 95% CI¼ 0.53 to 2.13,
P ¼ .87) (Figure 3A). Patients with HER2-enriched genomic pro-
files received statistically significant benefit from trastuzumab,
compared with chemotherapy alone (HR¼ 0.68. 95% CI¼ 0.52 to
0.89, P ¼ .005) (Figure 3B). Patients with luminal A profiles ex-
hibited a quantitative trend towards improved RFS, although
this trend did not achieve statistical significance (HR¼ 0.62, 95%
CI¼ 0.30 to 1.26, P ¼ .20) (blue curve vs green curve in Figure 3C).
HER2þ tumors with luminal B profiles benefitted statistically
significantly (HR¼ 0.45, 95% CI¼ 0.22 to 0.88, P ¼ .02) (red curve
vs brown curve in Figure 3C). Because of the small number of
Table 1. Comparison of Prosigna intrinsic subtype, risk of recurrence,
and risk category in arm A (chemotherapy alone) and arm B/C (che-
motherapy plus trastuzumab) of N9831
Subtype Arm A No. (%) Arm B/C No. (%) P*
Basal 38 (7.9) 59 (6.5) .76
HER2 342 (70.7) 662 (72.9)
Luminal A 47 (9.7) 85 (9.4)
Luminal B 57 (11.7) 102 (11.2)
ROR
1. <70 140 (28.9) 207 (22.8) .03
2. 70–81 116 (23.9) 220 (24.2)
3. 82–91 108 (22.3) 240 (26.4)
4. 92–100 120 (24.7) 241 (26.5)
Risk category
High 462 (95.4) 873 (96.1) .54
Intermediate/low 22 (4.5) 35 (3.8)
*P value from Chi-squared test for nominal categories or Cochran-Mantel-
Haenszel test for ordered categories. All statistical tests were two-sided. HER2 ¼
human epidermal growth factor receptor 2; ROR ¼ risk of recurrence.
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events in patients with luminal-type tumors, we combined
the luminal A and B tumors into a single cohort of luminal-
type tumors for subsequent analyses. Trastuzumab provided
statistically significant benefit in patients whose tumors
exhibited luminal profiles (HR¼ 0.52, 95% CI¼ 0.32 to 0.85, P ¼
.01) (Figure 3D).
A Cox model was used to evaluate RFS among basal and
nonbasal tumors. The hazard ratios for RFS of basal-like tumors
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Figure 1. Risk of recurrence (ROR) scores and RISK categories among human epidermal growth factor receptor 2–positive (HER2þ) tumors. The Prosigna algorithm re-
ports two scores, ROR and RISK. The associations between ROR scores and relapse-free survival (RFS) after chemotherapy (A) or chemotherapy plus trastuzumab (B) are
shown. The majority of the HER2þ tumors were assigned as high risk. The associations between RISK category and RFS after chemotherapy (C) or chemotherapy plus
trastuzumab (D) are given. Kaplan-Meier log-rank survival analysis (two-sided) was used to calculate P values. RFS ¼ relapse-free survival; ROR ¼ risk of recurrence
score, according to the Prosigna algorithm.;
Table 2. Basal-like HER2þ tumors exhibit lower ERBB2 expression and higher proliferation*
Subtype
ERBB2 mRNA
(95% CI) P†
% IHC 3þ cells
(95% CI) P†
Proliferative
score (95% CI) P†
Ki67
mRNA (95% CI) P†
Mitotic
score (95% CI) P†
Basal-like (n¼ 56) 10.8 (11.3 to 10.4) Ref 49.2 (61.9 to 36.5) Ref 6.91 (7.03 to 6.78) Ref 7.93 (8.07 to 7.79) Ref 2.55 (2.74 to 2.36) Ref
HER2-enriched
(n¼607)
13.0 (13.1 to 12.9) <.001 91.2 (92.9 to 89.4) <.001 6.52 (6.56 to 6.48) <.001 7.50 (7.55 to 7.45) <.001 2.01 (2.08 to 1.94) <.001
Luminal A (n¼ 75) 11.7 (12.0 to 11.4) .002 64.6 (74.6 to 54.6) .03 5.78 (5.90 to 5.65) <.001 6.79 (695 to 6.62) <.001 1.37 (1.52 to 1.22) <.001
Luminal B (n¼ 104) 11.1 (11.4 to 10.6) .11 45.8 (55.2 to 36.4) .67 6.56 (6.68 to 6.44) <.001 7.49 (7.61 to 7.37) <.001 1.56 (1.71 to 1.40) <.001
Luminal all (n¼ 179) 11.4 (11.6 to 11.2) .01 54.2 (61.2 to 47.3) .42 6.23 (6.34 to 6.13) <.001 7.20 (7.30 to 7.09) <.001 1.48 (1.60 to 1.37) <.001
*Data are summarized from 842 samples from arm A (445) and arm C (397 that were analyzed using the OncotypeDX 21-gene signature (9). Proliferative score is the av-
erage of five proliferative marker genes in this panel. Mitotic score was determined by histological examination by F. Baehner. All mRNA abundance data were normal-
ized and scaled to log base 2. Immunohistochemistry staining for human epidermal growth factor receptor 2 abundance (%3þ cells) were extracted from the clinical
record, as previously described. % IHC 3þ¼ percent of tumor cells with membrane scoring 3þ by clinical pathology; Ki67 ¼mRNA encoded byMKI67.
† Mann-Whitney U test, two-sided P value for comparison with basal-like tumors.
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in arm A did not appear to be statistically significantly different
from those of nonbasal tumors after chemotherapy (arm A
basal-like vs arm A nonbasal: HR¼ 0.76, 95% CI¼ 0.43 to 1.34,
P ¼ .34) (Table 3). In addition, RFS was not statistically signifi-
cantly different between basal-like tumors after chemotherapy vs
after chemotherapy plus trastuzumab (arm A basal-like vs arm B/
C basal-like: HR¼ 1.06, 95% CI¼ 0.53 to 2.13, P ¼ .87) (Table 3). As
expected, RFS among the nonbasal cohort was statistically signifi-
cantly improved by trastuzumab (arm A nonbasal vs arm B/C
nonbasal: HR¼ 0.65, 95% CI¼ 0.51 to 0.82, P < .001) (Table 3).
Moreover, RFS after trastuzumab was statistically significantly
better among non-basal-like tumors (arm B/C basal-like vs arm B/
C non-basal-like: HR¼ 0.47, 95% CI¼ 0.29 to 0.74, P ¼ .001)
(Table 3). However, the test for interaction of treatment arm (A vs
B/C) by tumor subtype (basal vs nonbasal) did not achieve statisti-
cal significance (P ¼ .20), which may or may not be because of the
small number of basal-like tumors in our sample cohort.
Hormone Receptor Status and Outcome Among
Nonbasal Tumors
Because basal-like tumors are generally estrogen receptor (ER)–
and/or progesterone receptor (PR)–negative, we evaluated the
association between subtype, outcome, and ER/PR status.
Patients with ER/PR-positive or ER/PR-negative non-basal-like
tumors had similar RFS after chemotherapy (arm A ER/PR-neg
vs arm A ER/PR-pos: HR¼ 0.90, 95% CI¼ 0.63 to 1.28, P ¼ .55)
(Table 3). Likewise, ER/PR status was not statistically signifi-
cantly associated with outcome after trastuzumab treatment of
nonbasal tumors (arm B/C ER/PR-neg vs arm B/C ER/PR-pos:
HR¼ 0.84, 95% CI¼ 0.62 to 1.14, P ¼ .27) (Table 3). Moreover, both
patients with ER/PR-positive and -negative tumors with
nonbasal features appeared to benefit from trastuzumab (arm A
ER/PR-neg vs arm B/C ER/PR-neg: HR¼ 0.67, 95% CI¼ 0.47 to 0.85,
P ¼ .02; arm A ER/PR-pos vs arm B/C ER/PR-pos: HR¼ 0.62, 95%
CI¼ 0.45 to 0.85, P ¼ .003) (Table 3).
Discussion
Intrinsic subtype, defined by abundance of transcripts that cor-
respond to the PAM50 cohort of genes, has gained wide accep-
tance as a tool for stratifying breast tumors based on the extent
to which these tumors exhibit expression profiles that corre-
spond to basal-like, HER2-enriched, luminal A, or luminal B
samples. All of the samples included in this analysis were cen-
trally evaluated for HER2 protein or gene copy number at the
Mayo Clinic (7). Thus, our data reflect molecular heterogeneity
within clinically well-defined HER2þ tumors, such that some
HER2þ tumors exhibit basal-like or luminal gene expression
profiles. These results are consistent with others published
elsewhere (10,11). Evaluation of several molecular features asso-
ciated with subtype suggests that there are statistically signifi-
cant differences in HER2 expression and proliferation. Most
notably, the basal-like tumors exhibited statistically signifi-
cantly lower HER2 mRNA and percent of cells staining 3þ for
HER2, coupled with high proliferative markers. Both of these
features might plausibly be associated with outcome.
To our knowledge, this is the first report of the use of the
Prosigna algorithm to define intrinsic subtype distribution and
outcome following adjuvant trastuzumab therapy of HER2þ tu-
mors. Our data are broadly consistent with analyses of intrinsic
subtype among HER2þ tumors from The Cancer Genome Atlas
(10), the NOAH neoadjuvant (11), and the NSABP B31 adjuvant
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Figure 2 Intrinsic subtype and relapse-free survival (RFS) among patients in the
N9831 trial. The relationship between RFS and time, evaluated as a function of
Prosigna subtype in all arms of the N9831 trial, is shown in (A). The relationship
between RFS and subtype in patients enrolled in arm A, chemotherapy alone, is
shown in (B), whereas RFS as a function of subtype in patients enrolled in arm
B/C, chemotherapy plus trastuzumab, is given in (C). Kaplan-Meier log-rank P
values (two-sided) were calculated. The Cox model (two-sided) was used to esti-
mate hazard ratios.
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trastuzumab trials (12), in which the research PAM50 algorithm
was used to assess molecular heterogeneity among tumors that
are clinically defined as HER2þ. The key question is to what ex-
tent this molecular heterogeneity is associated with clinical out-
come following trastuzumab. As reported in the NOAH and
NSABP B31/PAM50 analysis, we observed that HER2þ tumors
with HER2-enriched profiles are generally responsive to trastu-
zumab. Thus, the HER2-enriched profile is predictive of better
outcome following adjuvant trastuzumab. The data with the
HER2þ luminal subtypes are somewhat more difficult to evalu-
ate. These patients tend to do very well, and few events were re-
corded. We observed a qualitative trend toward increased RFS
in trastuzumab-treated patients with both luminal A and lumi-
nal B tumors, although statistical significance was not achieved
with the luminal A subgroup. Nevertheless, the data suggest
that HER2þ patients whose tumors express luminal signatures
likely receive additional benefit from trastuzumab, above and
beyond that received from chemotherapy alone.
The majority of the HER2þ tumors were classified as high
risk by both Prosigna and OncotypeDX. It is unclear if the small
subset of patients with low/intermediate risk, estrogen and/or
progesterone receptor–positive early-stage HER2þ tumors
require adjuvant trastuzumab. The number of such patients en-
rolled in N9831 was small. Additional studies will be required to
assess the relationship between risk category and RFS among
patients with hormone receptor–positive tumors.
The data indicate that nonbasal HER2þ tumors (ie, those tu-
mors with HER2-enriched, luminal A, or luminal B profiles) are
responsive to trastuzumab, irrespective of hormone receptor
status. A subset, about 7%, of HER2þ tumors in the N9831 study
exhibited gene expression profiles that resemble those of basal-
like tumors. Similar results were observed in analysis of 1225
samples from The Cancer Genome Atlas Network and
METABRIC databases (14.1% basal-like) (13) and 1579 samples
from the NSABP B31 trial (6.5% basal-like) (12). The data pre-
sented here suggest that HER2þ tumors with basal-like features
may benefit less from adjuvant trastuzumab. This suggestion is
consistent with the molecular features of these tumors, which
express low levels of HER2 and appear to be highly proliferative.
However, the conclusion that patients with such tumors will
not benefit from trastuzumab is not warranted by the data.
Although the hazard ratio for RFS following trastuzumab is not
statistically significantly different from that observed with che-
motherapy alone (HR¼ 1.06, P ¼ .87), the 95% confidence
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Figure 3. Human epidermal growth factor receptor 2–positive (HER2þ) tumors with basal-like expression profiles compared with tumors with HER2-enriched or lumi-
nal-type expression profiles. Relapse-free survival, plotted as Kaplan-Meier curves was compared for arm A (chemotherapy alone) vs arm B/C (chemotherapy plus tras-
tuzumab) for N9831 tumors with basal-like (A) or HER2-enriched (B) Prosignal subtype profiles. Log-rank statistics were used to calculate P values for relapse-free
survival (RFS) as a continuous variable. Hazard ratios on the basis of % RFS 10 years following random assignment. Survival analysis was also carried out for luminal A
and luminal B subtypes, individually (C) and combined into a luminal-type category (D). All statistical tests were two-sided.
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intervals are very large (95% CI¼ 0.53 to 2.13), and the test for in-
teraction between treatment and subtype (basal vs nonbasal)
was not statistically significant. Moreover, Pogue-Geile et al. re-
ported that basal-like tumors in the NSABP B31 trial received
statistically significant benefit from adjuvant trastuzumab (12).
There are some differences in the algorithms used to call intrin-
sic subtype in our study and the study by Pogue-Geile et al.
They reported disease-free survival, whereas we report breast
cancer relapse–free survival. Perhaps more importantly, they
used a modified version of the PAM50 algorithm, rather than
the Prosigna algorithm used in our studies. These two algo-
rithms use different normalization strategies, and they called
47% of the HER2þ tumors in B31 HER2-enriched, whereas we
called 73% of the N9831 HER2þ samples HER2-enriched.
Furthermore, both studies were limited in power by the relative
small number of basal-like tumors that were identified. Given
these considerations, we are inclined to the most conservative
conclusion: that additional studies will be required to sort out
the role of intrinsic subtype in predicting response to HER2-
targeted therapy in the adjuvant setting.
There are a couple of limitations of this study. The first is that
it is a retrospective analysis of samples from less than half of the
patients enrolled on N9831. This because of the fact that the sub-
mission of patient samples was optional for this study and some
samples were dropped due to poor quality. It is recognized that
this could bias the results. A comparison of patients with samples
used in this analysis to patients not included in the analysis only
showed some clinical-pathological differences (eg, patients with
larger tumors are included in this analysis), but there was no dif-
ference observed in the treatment effect between the patients in-
cluded in this study and patients not included in this study.
Another limitation is that some of the identified intrinsic subtype
groups had a relatively small number of patients and events. This
limits the power of the analyses in these subgroups, which makes
statistically nonsignificant results hard to interpret: They could
be reflective of no real difference between the groups or could be
because of lack of power to detect a difference of interest.
Finally, our data indicate that evaluation of HER2 status by IHC
and/or FISH is an essential component of clinical management of
breast cancer patients. Intrinsic subtype alone cannot replace con-
ventional histopathological evaluation of HER2 status because
many tumors that are classified as luminal A or luminal B will ben-
efit from adjuvant trastuzumab if that subtype is accompanied by
HER2 overexpression. However, among tumors that overexpress
HER2, we speculate that assessment of intrinsic subtype may guide
further treatment development, particularly with respect to evalu-
ating alternative therapeutic approaches for that subset of HER2þ
tumors of the basal-like subtype. Given the relative rarity of such
tumors, additional studies will be required to evaluate this idea.
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Table 3. HER2þ tumors with basal-like signatures have different outcomes than HER2þ tumors with nonbasal signatures*
Arm Subtype or hormone receptor status No. Events (%) HR (95% CI) P
RFS as a function of subtype (basal vs nonbasal) by treatment arm
A Basal-like 38 13 (34.2) 1.0 (Ref)
A Non-basal-like 446 123 (27.5) 0.76 (0.43 to 1.34) .34
B/C Basal-like 59 20 (33.8) 1.0 (Ref)
B/C Non-basal-like 849 161 (19.0) 0.47 (0.29 to 0.74) .001
RFS as a function of treatment (arm A vs arm B/C) by subtype
A Basal-like 38 13 (34.2) 1.0 (Ref)
B/C Basal-like 59 20 (33.8) 1.06 (0.53 to 2.13) .87
A Non-basal-like 446 123 (27.5) 1.0 (Ref)
B/C Non-basal-like 849 161 (19.0) 0.65 (0.51 to 0.82) <.001
RFS by ER/PR status as a function of arm within nonbasal tumors
A ER/PR-negative 192 54 (28.1) 1.0 (Ref)
A ER/PR-positive 254 69 (27.2) 0.90 (0.63 to 1.28) .55
B/C ER/PR-negative 381 76 (19.9) 1.0 (Ref)
B/C ER/PR-positive 468 85 (18.2) 0.84 (0.62 to 1.14) .27
RFS by treatment arm and ER/PR status with nonbasal tumors
A ER/PR-negative 192 54 (28.1) 1.0 (Ref)
B/C ER/PR-negative 381 76 (19.9) 0.67 (0.47 to 0.95) .02
A ER/PR-positive 254 69 (27.2) 1.0 (Ref)
B/C ER/PR-positive 468 85 (18.2) 0.62 (0.45 to 0.85) .003
*Cox model analysis was carried out to compare relapse-free survival between basal-like and nonbasal tumors in arm A or in arm C. In addition, the Cox model was
used to compare outcome as a function of treatment (arm A vs arm B/C) as a function of basal-like or nonbasal subtype. Test for interaction of arm and basal subtype
status P ¼ .20. A Cox model analysis was used to define hazard ratio (HR) for recurrence as a function of estrogen receptor/progesterone receptor (ER/PR) status and
treatment. Wald Chi-squared P values were calculated from the Cox model data. The effect of treatment (arm A vs arm B/C) is shown as a function of ER/PR status. Test
for interaction of arm and HR status P ¼ .79. All statistical tests were two-sided. ER ¼ estrogen receptor–alpha, the product of ESR1; HER2 ¼ human epidermal growth
factor receptor; PR ¼ progesterone receptor, the product of PGR; Ref ¼ referent; RFS ¼ relapse-free survival, as defined in “Methods.”
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